0001213900-24-061942.txt : 20240717 0001213900-24-061942.hdr.sgml : 20240717 20240717083032 ACCESSION NUMBER: 0001213900-24-061942 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240717 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240717 DATE AS OF CHANGE: 20240717 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Longeveron Inc. CENTRAL INDEX KEY: 0001721484 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 472174146 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40060 FILM NUMBER: 241121020 BUSINESS ADDRESS: STREET 1: 1951 NW 7TH AVENUE STREET 2: SUITE 520 CITY: MIAMI STATE: FL ZIP: 33136 BUSINESS PHONE: 305-302-7158 MAIL ADDRESS: STREET 1: 1951 NW 7TH AVENUE STREET 2: SUITE 520 CITY: MIAMI STATE: FL ZIP: 33136 FORMER COMPANY: FORMER CONFORMED NAME: LONGEVERON LLC DATE OF NAME CHANGE: 20171101 8-K 1 ea0209541-8k_longeveron.htm CURRENT REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 17, 2024

Longeveron Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40060		47-2174146
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1951 NW 7th Avenue, Suite 520

Miami, Florida 33136

(Address of Principal Executive Offices)

Registrant’s Telephone Number, Including Area Code: (305) 909-0840

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.001 par value per share		LGVN		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events

On July 17, 2024, Longeveron Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for the Company’s lead investigational product Lomecel-B^TM, an allogeneic medicinal signaling cell therapy product isolated from the bone marrow of young, healthy adult donors, for the treatment of mild Alzheimer’s disease. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

Fast Track designation is available to a product if it is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening disease or condition (or serious aspect of a condition), and it demonstrates the potential to address unmet medical needs for such a disease or condition (i.e., there is no available therapy for the condition, or the condition’s treatment or diagnosis is not adequately addressed by currently available therapies). This designation is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions so that an approved product may reach the market expeditiously. Investigational therapies that receive Fast Track designation may be eligible for Priority Review (i.e., review of an application within six (6) months of receipt versus 10 months) if relevant criteria are met at the time of application submission to the FDA, as well as rolling FDA review (i.e., the FDA may consider reviewing portions of an application before the complete application is submitted).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

Exhibit No.		Description
99.1		Press Release issued by the Company on July 17, 2024
104		Cover Page Interactive Data File (formatted as Inline XBRL)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	LONGEVERON INC.

Date: July 17, 2024	/s/ Wa’el Hashad
	Name:	Wa’el Hashad
	Title:	Chief Executive Officer

2

EX-99.1 2 ea020954101ex99-1_longeveron.htm PRESS RELEASE ISSUED BY THE COMPANY ON JULY 17, 2024

Exhibit 99.1

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B^TM for the Treatment of Mild Alzheimer’s Disease

– FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ –

– Second designation received for Lomecel-B^TM for the treatment of mild Alzheimer’s Disease after Regenerative Medicine Advanced Therapeutics (RMAT) Designation announced on July 9, 2024 –

– Phase 2a Lomecel-B^TM data in mild Alzheimer’s Disease selected for Featured Research Session oral presentation and poster presentation at upcoming Alzheimer’s Association International Conference® (AAIC) –

MIAMI, July 17, 2024 -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lomecel-B^TM for the treatment of mild Alzheimer’s Disease. Lomecel-B^TM is a proprietary, scalable, allogeneic, investigational cellular therapy being evaluated across multiple indications, including Alzheimer’s Disease (Phase 2a completed), Aging-related Frailty (Phase 2b completed) and hypoplastic left heart syndrome (HLHS) (Phase 2b ongoing).

“Fast Track designation is another important milestone for Longeveron and Lomecel-B^TM, which, along with the recent granting of Regenerative Medicine Advanced Therapy (RMAT) designation, recognizes the critical need to quickly advance novel, safe and effective investigational treatments for Alzheimer’s Disease, which has a devastating impact on patients and their families,” said Wa’el Hashad, Chief Executive Officer of Longeveron. “Alzheimer’s Disease is a neurodegenerative disorder that leads to progressive memory loss and death, and its tremendous impact on our aging population is exacerbated by a lack of therapeutic options that slow disease progression or improve cognitive function. We believe that Lomecel-B^TM, which demonstrated an overall slowing/prevention of disease worsening compared to placebo in the CLEAR MIND Phase 2a clinical trial, has the potential to become an important treatment option for physicians and patients, and we look forward to sharing the latest data with the Alzheimer’s Disease research and patient communities at AAIC 2024.”

The FDA’s Fast Track designation process is designed to facilitate the development and expedite the review of new therapies intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Investigational therapies that receive Fast Track designation may be eligible for Priority Review if relevant criteria are met at the time of application submission to FDA, and rolling FDA review.

The Fast Track designation granted to the Lomecel-B^TM Alzheimer’s Disease program is the fifth special regulatory designation received for Lomecel-B^TM. The Lomecel-B^TM Alzheimer’s Disease program has also been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA, while the Lomecel-B^TM HLHS program has received three FDA designations: Orphan Drug designation, Fast Track designation and Rare Pediatric Disease designation.

Upcoming Presentation at the Alzheimer’s Association International Conference® (AAIC)

The Fast Track designation and continued clinical development of Lomecel-B^TM are based upon positive topline data reported from the Phase 2a CLEAR MIND clinical trial. Full results from the CLEAR MIND clinical trial evaluating Lomecel-B^TM in mild Alzheimer’s Disease have been selected for a Featured Research Session oral presentation and poster presentation at AAIC, taking place July 28 – August 1, 2024, in Philadelphia and online. Longeveron Co-Founder, Chief Scientific Officer and Chairman Joshua M. Hare, MD, FACC, FAHA, was invited to chair this Featured Research Session.

Details of the presentations at AAIC are as follows:

Oral Presentation

Date: Sunday, July 28, 2024

Time: 4:15 pm – 5:45pm EDT

Session: Featured Research Session, 1-32-FRS-B

Title: Results from a Phase 2a Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Lomecel-B^TM in Mild Alzheimer’s Disease Dementia

Poster Presentation

Date: Tuesday, July 30, 2024

Time: 7:30am – 4:15pm EDT

Session: In-Person Posters Tuesday; Drug Development

Topic: MRI Imaging results in the CLEAR MIND phase 2a clinical trial of Lomecel-B^TM

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an investigational allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s Disease, and Aging-related Frailty. Lomecel-B^TM development programs have received five separate and distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the Alzheimer’s Disease program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Forward-Looking Statements

Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects and include, but are not limited to, the potential for Lomecel-B^TM to be an effective treatment for mild Alzheimer’s Disease or achieve U.S. FDA approval under the Fast Track designation program. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, market and other conditions, our limited operating history and lack of products approved for commercial sale; adverse global conditions, including macroeconomic uncertainty; inability to raise additional capital necessary to continue as a going concern; our history of losses and inability to achieve profitability going forward; the absence of FDA-approved allogenic, cell-based therapies for Aging-related Frailty, Alzheimer’s Disease, or other aging-related conditions, or for HLHS or other cardiac-related indications; ethical and other concerns surrounding the use of stem cell therapy or human tissue; our exposure to product liability claims arising from the use of our product candidates or future products in individuals, for which we may not be able to obtain adequate product liability insurance; the adequacy of our trade secret and patent position to protect our product candidates and their uses: others could compete against us more directly, which could harm our business and have a material adverse effect on our business, financial condition, and results of operations; if certain license agreements are terminated, our ability to continue clinical trials and commercially market products could be adversely affected; the inability to protect the confidentiality of our proprietary information, trade secrets, and know-how; third-party claims of intellectual property infringement may prevent or delay our product development efforts; intellectual property rights do not necessarily address all potential threats to our competitive advantage; the inability to successfully develop and commercialize our product candidates and obtain the necessary regulatory approvals; we cannot market and sell our product candidates in the U.S. or in other countries if we fail to obtain the necessary regulatory approvals; final marketing approval of our product candidates by the FDA or other regulatory authorities for commercial use may be delayed, limited, or denied, any of which could adversely affect our ability to generate operating revenues; we may not be able to secure and maintain research institutions to conduct our clinical trials; ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations; if we receive regulatory approval of Lomecel-B™ or any of our other product candidates, we will be subject to ongoing regulatory requirements and continued regulatory review, which may result in significant additional expense; being subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our therapeutic candidates; reliance on third parties to conduct certain aspects of our preclinical studies and clinical trials; interim, “topline” and preliminary data from our clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data; the volatility of price of our Class A common stock; we could lose our listing on the Nasdaq Capital Market; provisions in our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our Class A common stock; we have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators; and in order to successfully implement our plans and strategies, we will need to grow our organization, and we may experience difficulties in managing this growth. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on February 27, 2024, as amended by the Annual Report on Form 10-K/A filed March 11, 2024, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact:

Derek Cole

Investor Relations Advisory Solutions

derek.cole@iradvisory.com

Media Contact:

Andrea Cohen

Sam Brown Inc. Healthcare Communications

andreacohen@sambrown.com

(917) 209-7163

EX-101.SCH 3 lgvn-20240717.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lgvn-20240717_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 lgvn-20240717_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Jul. 17, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jul. 17, 2024
Entity File Number	001-40060
Entity Registrant Name	Longeveron Inc.
Entity Central Index Key	0001721484
Entity Tax Identification Number	47-2174146
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1951 NW 7th Avenue
Entity Address, Address Line Two	Suite 520
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33136
City Area Code	(305)
Local Phone Number	909-0840
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Class A Common Stock, $0.001
Trading Symbol	LGVN
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,]#\5@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #/0_%8OV-S4>\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>R$E&"R;-9:6G#08K;.QF;+4UB_]@:R1]^R5>FS*V!]C1TL^? M/H%:%83R$9^C#QC)8+H;;>^24&'#3D1! "1U0BM3.27+3I*4)45L&Z> M&,YCW\(-,,,(HTW?!=0+,5?_Q.8.L$MR3&9)#<-0#DW.33M4\/;T^)+7+8Q+ M))W"Z5&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #/0_%898CFCX4$ #2$0 & 'AL+W=O_E2$V3?=U>/UNYOE'XR:\XM>4EB:0;>VMKTHM$PX9HGS)RI ME$OX9JETPBR]E5F8R'Y5!.3)0G3 MKY<\5IN!1[VW#Q[$:FW=!XUA/V4K/N/V6SK5<-8H5"*1<&F$DD3SY< ;T8O+ MH.,"\BN^"[XQ>\?$WL5O MNL#]XS?UF_SFX686S/"QBA]%9-<#K^>1B"]9%ML'M?F#[VZH[?1"%9O\+]EL MKVW['@DS8U6R"P:"1,CM?_:R2\1>0/-00+ +"'+N[0_EE%?,LF%?JPW1[FI0 M;1 ">DJ\K,:OA60)P=CM4SU_V&!2GW02/._V"0+0*B!:J,@*"**>X MB=FJB@*/7[+8<(2C77"TCTO&E&NA(G(M(P+-5YD77*EHH[H^ZA1H'53P6EIA M7\F-B#F99,FBNK=Q#=^GIRTP-1_AZ18\W6-X'OA*N,Z&G$U84IDH7.=.R16' M)0(^=BO#,X2L5Y#UCB$;0QTUBT$UXB_D"W^M8L.5?$A8-Z"M'E; \P+K_!BL M.7LAMQ&PB:4(6>[?A\N)*[:ZIP'MMFBK@^!1O_1+_QA J(+2J=(YVPF96>A_ MHC09JPP2"GE54669:]2OKC'(/5.GQT".H@BLT)R\'9 [N(Y\E=5DN"0];U,R M>21=NR:C9RXSS$EHZ?L4M6V<=+Y1E:2XY"P34(MV@*U?6AH_Q:W[/>#8G4&A MYVHC*^%PN7O!$H&!E9L!Q=W\/5C1@E.MGH4,JXN,:][<86CE_D!Q6W^/-E7& M@L?\+=+#ZP)7;#9I$UV_Y09!<7?/ZS>" ?8P"B[PL>FW/V$HY=Y ZTP]A*Q, MUTIBFU6-R+E_?NKW6FBSEWL"Q:W\40MKN834)$DF=\YK*JEPH;I1@Y;[ <7M M>Z9B$0HKY(K<0X-KP>)*'ERECB&PPK83(0QE,+M^72ZK MZU>C5TM6FGZ ._3_R&Z-R8"L%A"7K079M!O ME1,'KE0][(]C9LPOH[QY85Z8614^G9!?_3.83VH?!()R0PAP!Y]K%KENG+TF M"U79BS4"=Y^_3S"2<@<(<+=^2R"Y?@G7# ;$@\-EC=!D-+L:_84QE=8?'&7] MUPG7*Y>ESZ $P/4)&6RNM2XH-7HI!&4QA_4/!JX%P$\(A,%:U:1;X83N^:0 M.^O61T2@KM*(?-3T-W;CGOFTF-(S)<@Y)]U(0EZ^P)A M>V)5FC^T+Y2U*LD/UYS!.G87P/=+I>S;B7L/4+S&&?X$4$L#!!0 ( ,]# M\5B?H!OPL0( .(, - >&PO9 MKEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R M6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8 MRY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>% ME#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY M85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$ M&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ* M3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"? M@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S M/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM M%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&89 M4IT,/O'^8* \^>Q\ETWLJ.?]74_P$ M4$L#!!0 ( ,]#\5B7BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://longeveron.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea0209541-8k_longeveron.htm lgvn-20240717.xsd lgvn-20240717_lab.xml lgvn-20240717_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0209541-8k_longeveron.htm": { "nsprefix": "LGVN", "nsuri": "http://longeveron.com/20240717", "dts": { "inline": { "local": [ "ea0209541-8k_longeveron.htm" ] }, "schema": { "local": [ "lgvn-20240717.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "lgvn-20240717_lab.xml" ] }, "presentationLink": { "local": [ "lgvn-20240717_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://longeveron.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-07-17", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0209541-8k_longeveron.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-07-17", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0209541-8k_longeveron.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://longeveron.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-24-061942-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-061942-xbrl.zip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end XML 17 ea0209541-8k_longeveron_htm.xml IDEA: XBRL DOCUMENT 0001721484 2024-07-17 2024-07-17 iso4217:USD shares iso4217:USD shares false 0001721484 8-K 2024-07-17 Longeveron Inc. DE 001-40060 47-2174146 1951 NW 7th Avenue Suite 520 Miami FL 33136 (305) 909-0840 false false false false Class A Common Stock, $0.001 LGVN NASDAQ true false